Renaissance Group LLC Lowers Stock Holdings in Cencora, Inc. (NYSE:COR)

Renaissance Group LLC trimmed its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 91.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,614 shares of the company's stock after selling 119,828 shares during the quarter. Renaissance Group LLC's holdings in Cencora were worth $2,385,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. United Bank raised its holdings in shares of Cencora by 4.2% in the third quarter. United Bank now owns 5,601 shares of the company's stock valued at $1,261,000 after acquiring an additional 225 shares in the last quarter. Arete Wealth Advisors LLC boosted its stake in Cencora by 4.9% in the 3rd quarter. Arete Wealth Advisors LLC now owns 2,412 shares of the company's stock worth $541,000 after purchasing an additional 113 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in shares of Cencora by 32.5% during the third quarter. EP Wealth Advisors LLC now owns 5,279 shares of the company's stock valued at $1,188,000 after buying an additional 1,296 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Cencora in the third quarter valued at about $521,000. Finally, Orion Portfolio Solutions LLC increased its holdings in Cencora by 3.8% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 12,491 shares of the company's stock worth $2,812,000 after buying an additional 457 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,675 shares of company stock valued at $8,034,778. 10.80% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Wells Fargo & Company upped their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Bank of America lifted their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average price target of $284.20.

Cencora Trading Down 0.3 %

Shares of COR stock traded down $0.74 during trading hours on Monday, hitting $283.59. The company had a trading volume of 282,085 shares, compared to its average volume of 1,709,523. The stock has a market capitalization of $54.99 billion, a PE ratio of 40.34, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65. The company's fifty day moving average is $260.27 and its 200 day moving average is $245.16.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.78%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.